Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Authors
Ledermann, Jonathan AHackshaw, Allan
Kaye, Stan B
Jayson, Gordon C
Gabra, Hani
McNeish, Iain
Earl, Helena
Perren, Timothy J
Gore, Martin
Persic, Mojca
Adams, Malcolm
James, Lindsay
Temple, Graham
Merger, Michael
Rustin, Gordon J S
Affiliation
Cancer Research UK and University College London Cancer Trials Centre, UCL Cancer Institute, University College London, 90 Tottenham Court Rd, London W1T 4TJ.Issue Date
2011-10-01
Metadata
Show full item recordAbstract
Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer. We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease.Citation
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. 2011, 29 (28):3798-804 J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2010.33.5208PubMed ID
21859991Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2010.33.5208